60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease...
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like...
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine...
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Hydreight Technologies Inc. has received final approval for its qualifying transaction as principally described in its filing statement dated November...
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that...
Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS DayBETHLEHEM, Pa., Dec. 01, 2022...
First-in-class bioprognostic™ KidneyIntelX provided clear direction for primary care physicians to slow or stop progression of chronic kidney disease in...
HAMILTON, BERMUDA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- BentrioTM nasal spray launched in Hong Kong by partner Nuance Pharma to...
SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily...
Fastlane Program Introduces Selected Startups to Leading Global Automotive Brands in the Mobility IndustryNESS ZIONA, Israel, Nov. 30, 2022 (GLOBE...
NEWTON, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition,...
NEW YORK, Nov. 30, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a...
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators...
Hamilton, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Initiative is Nuance’s first step in penetrating Chinese market with BentrioTMDensely populated...
AGOURA HILLS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer...
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal...
AUM302 has potential to be the first multi-kinase inhibitor class of drug in NeuroblastomaSINGAPORE and BETHESDA, Md., Nov. 30, 2022...
Shineco, Inc. Dr. Marvin Liu (second person from the left) introduced products to customers on siteBEIJING, Nov. 29, 2022 (GLOBE...
Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora TherapeuticsSAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) --...